CTLA4 and central nervous system cancer: The expression of immune checkpoint molecules such as programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is markedly increased in gliomas, inhibiting the activity of effector T cells and inducing the expansion of Tregs [17, 18].